Baillie Gifford - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2023$1,356
+8.6%
1010.0%0.00%
Q4 2022$1,249
+24.9%
1010.0%0.00%
Q3 2022$1,0000.0%1010.0%0.00%
Q2 2022$1,000
-50.0%
1010.0%0.00%
Q1 2022$2,0000.0%1010.0%0.00%
Q4 2021$2,000
+100.0%
1010.0%0.00%
Q3 2021$1,000
-50.0%
1010.0%0.00%
Q2 2021$2,0000.0%1010.0%0.00%
Q1 2021$2,0000.0%101
+17.4%
0.00%
Q4 2020$2,000860.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders